However, treatment with either siRNA against PKCα, -β or -ζ did not substantially decrease those mesenchymal markers, suggesting a distinctive role of PKCδ among the isoforms in mesenchymal transformation of GBM cells (Fig. S1E). This evidence concerns the gene PRKCD and glioblastoma.